ArticleThe Canadian journal of infectious diseases = Journal canadien des maladies infectieuses1998
Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.
Article in The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- Simultaneous electrochemical detection of imipenem and meropenem using a Pt-Au bimetallic nanoparticle-decorated 3D graphene oxide modified glassy carbon electrode.Scientific reports · 2026Article
- Review
- "Bilateral Capnocytophaga Canimorsus Periprosthetic Joint Infections in an Immunocompromised Patient: A Case Report and Literature Review".Arthroplasty today · 2025Article
- Nanotechnology-powered Meningitis Therapies: Lipid Nanoparticles Lead the Way.Current pharmaceutical biotechnology · 2025Review
- Therapeutic drug monitoring of six contraindicated/co-administered drugs by simple and green RP-HPLC-PDA; application to spiked human plasma.BMC chemistry · 2024Article
- Predictors of Treatment Failure and Mortality among Patients with Septic Shock Treated with Meropenem in the Intensive Care Unit.The Malaysian journal of medical sciences : MJMS · 2024Article
- Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Resistance Profile of Bacteria Causing Pediatric Infections at the University Teaching Hospital in Rwanda.The American journal of tropical medicine and hygiene · 2022Article
- Carbapenem resistance associated with coliuria among outpatient and hospitalised urology patients.New microbes and new infections · 2022Article
- Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-ResistantPharmaceutics · 2022Article
- Review
- Inter-species interactions alter antibiotic efficacy in bacterial communities.The ISME journal · 2022Article
- Antimicrobial Resistance in Enterobacteriaceae Bacteria Causing Infection in Trauma Patients: A 5-Year Experience from a Tertiary Trauma Center.Journal of laboratory physicians · 2021Article
- The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.The Journal of antimicrobial chemotherapy · 2021Review
- Development of Novel Peptides for the Antimicrobial Combination Therapy against Carbapenem-ResistantPharmaceutics · 2021Article
- Antibacterial and COX-2 Inhibitory Tetrahydrobisbenzylisoquinoline Alkaloids from the Philippine Medicinal PlantPlants (Basel, Switzerland) · 2021Article
- Meropenem Administered via Intravenous Regional Limb Perfusion for Orthopedic Sepsis in Horses: A Clinical Retrospective Study.Frontiers in veterinary science · 2021Article
- Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan.Scientific reports · 2020Observational
- The stability of carbapenems before and after admixture to PMMA-cement used for replacement surgery caused by Gram-negative bacteria.European journal of medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects. DATA SELECTION: MEDLINE search from 1975 to 1997 and follow-up of references. DATA EXTRACTION: Clinical trials comparing imipenem with meropenem, or either imipenem or meropenem with standard therapy in the treatment of serious infections were selected. DATA SYNTHESIS: Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram-positive cocci while meropenem is more active against Gram-negative bacilli. The agents display similar pharmacokinetics. Clinical studies in patients with serious infections (intra-abdominal infection, respiratory infection, septicemia, febrile neutropenia) report similar bacteriological and clinical cure rates with imipenem and meropenem. Meropenem is approved for the treatment of bacterial meningitis, whereas imipenem is not. Adverse effects are similar.
conclusionsCurrent literature supports the use of imipenem at a dose of 500 mg every 6 h and meropenem at 1 g every 8 h for the treatment of severe infections. For the treatment of serious infections, imipenem (500 mg every 6 h or 2 g/day [$98/day]) is more economical than meropenem (1 g every 8 h or 3 g/day [$142/day]) based on acquisition cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.